BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Accenture
McKesson
Cerilliant
Julphar
Johnson and Johnson
QuintilesIMS
Boehringer Ingelheim
Baxter
Chubb

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,501,760

« Back to Dashboard

Which drugs does patent 8,501,760 protect, and when does it expire?

Patent 8,501,760 protects TASIGNA and is included in one NDA.

This patent has forty patent family members in thirty countries.
Summary for Patent: 8,501,760
Title:Pharmaceutical compositions comprising nilotinib or its salt
Abstract: A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.
Inventor(s): Bruneau; Nathalie (Cran-Gevrier, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:13/624,354
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 8,501,760

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,501,760

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06121371Sep 27, 2006

Non-Orange Book US Patents Family Members for Patent 8,501,760

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,756 Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,501,760

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200821298 ➤ Subscribe
Tunisia 2009000093 ➤ Subscribe
Slovenia 2068839 ➤ Subscribe
Russian Federation 2469707 ➤ Subscribe
Russian Federation 2009115782 ➤ Subscribe
Portugal 2068839 ➤ Subscribe
Peru 13792008 ➤ Subscribe
Peru 06262012 ➤ Subscribe
New Zealand 575317 ➤ Subscribe
Norway 20091501 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Healthtrust
McKinsey
AstraZeneca
Cantor Fitzgerald
Fuji
Chinese Patent Office
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot